Why It Matters
The administration is targeting international pricing structures that rely on American pharmaceutical innovation to lower domestic costs.
What Happened
President Donald Trump secured nine new pricing agreements with drug manufacturers. The administration argues that wealthy foreign governments use price controls, mandatory rebates, and reimbursement delays to suppress medicine costs while benefiting from U.S. research.
Last year, the White House negotiated a deal requiring Britain to increase payments for new medicines by 25 percent. In June, the administration launched a formal investigation into how Germany’s drug price controls harmed American commerce. Japan subjects roughly half of newly launched medicines to annual price cuts, while France and Switzerland employ similar tactics to pay less for new drugs.
By the Numbers
Nine — New pricing agreements secured with drug manufacturers
Three-quarters — Share of pharmaceutical profits accounted for by American patients
Over half — Share of global research and development spending funded by U.S. patients
25 percent — Required increase in British payments for new medicines
Roughly half — Proportion of newly launched medicines in Japan subject to annual price cuts
More than $254 billion — Potential rise in global pharmaceutical revenue if developed countries paid U.S. prices
Zoom Out
America accounts for roughly three-quarters of pharmaceutical profits and over half of global research and development spending. Some members of Congress have proposed writing “most-favored-nation” drug pricing into law, which would tie U.S. prices to foreign rates. The administration argues that such measures would reduce R&D funding and threaten jobs.
What’s Next
An analysis states global pharmaceutical revenue would rise by more than $254 billion if developed countries paid U.S. prices. The investigation into Germany’s pricing policies continues as the administration pursues further international agreements.